Table 1

Quality of life—indirect comparison of testosterone products

Standardised mean difference (95% credible interval)*
PlaceboPatch,
5 mg/day
Gel 1%,
5 mg/day
Gel 1%,
50 mg/day
Gel 1%, 75 mg/dayGel 1%,
100 mg/day
Gel 2%,
60 mg/day
Oral TU,
160 mg/day
IM TU,
1000 mg/
10  weeks
IM TU,
1000 mg/
12  weeks
IM TE,
250 mg/
3  weeks
IM TE,
250 mg/
4 weeks
IM TC,
200 mg/
4  weeks
IM Sustanon, 100 mg/2 weeksIM Durateston, 250 mg/4 weeks
Patch,
5 mg/day
−0.33
(−0.97 to 0.31)
Gel 1%,
5 mg/day
−0.11
(−0.86 to 0.64)
0.21
(−0.78 to 1.20)
Gel 1%,
50 mg/day
−0.32
(−0.74 to 0.17)
0.01
(−0.76 to 0.82)
−0.20
(−1.05 to 0.69)
Gel 1%,
75 mg/day
−0.24
(−0.83 to 0.34)
0.09
(−0.78 to 0.95)
−0.12
(−1.09 to 0.82)
0.08
(−0.70 to 0.79)
Gel 1%,
100 mg/day
−0.19
(−0.94 to 0.55)
0.13
(−0.84 to 1.10)
−0.08
(−1.13 to 0.97)
0.12
(−0.78 to 0.96)
0.04
(−0.89 to 0.99)
Gel 2%,
60 mg/day
−0.29
(−1.01 to 0.44)
0.04
(−0.93 to 1.00)
−0.17
(−1.21 to 0.87)
0.03
(−0.85 to 0.86)
−0.05
(−0.96 to 0.89)
−0.09
(−1.12 to 0.94)
Oral TU,
160 mg/day
0.20
(−0.33 to 0.74)
0.53
(−0.30 to 1.36)
0.32
(−0.61 to 1.24)
0.52
(−0.21 to 1.19)
0.44
(−0.34 to 1.24)
0.40
(−0.51 to 1.31)
0.49
(−0.41 to 1.38)
IM TU, 1000 mg/10 weeks−0.21
(−0.96 to 0.56)
0.12
(−0.87 to 1.13)
−0.09
(−1.15 to 0.98)
0.11
(−0.80 to 0.98)
0.03
(−0.92 to 1.00)
−0.01
(−1.07 to 1.06)
0.08
(−0.97 to 1.14)
−0.41
(−1.35 to 0.53)
IM TU, 1000 mg/12 weeks −0.48
(−0.84 to –0.10)
−0.15
(−0.89 to 0.60)
−0.36
(−1.19 to 0.48)
−0.16
(−0.76 to 0.41)
−0.24
(−0.91 to 0.47)
−0.28
(−1.10 to 0.55)
−0.19
(−1.00 to 0.62)
−0.68
(−1.32 to –0.02)
−0.27
(−1.12 to 0.58)
IM TE, 250 mg/3 weeks−0.05
(−1.04 to 0.94)
0.28
(−0.47 to 1.03)
0.07
(−1.17 to 1.30)
0.27
(−0.85 to 1.33)
0.19
(−0.95 to 1.34)
0.15
(−1.09 to 1.37)
0.24
(−1.00 to 1.46)
−0.25
(−1.38 to 0.88)
0.16
(−1.10 to 1.40)
0.43
(−0.63 to 1.49)
IM TE,
250 mg/4 weeks
0.08
(−0.44 to 0.63)
0.41
(−0.41 to 1.26)
0.20
(−0.72 to 1.13)
0.40
(−0.32 to 1.09)
0.32
(−0.44 to 1.13)
0.28
(−0.62 to 1.21)
0.37
(−0.51 to 1.28)
−0.12
(−0.86 to 0.66)
0.29
(−0.64 to 1.22)
0.56
(−0.09 to 1.22)
0.13
(−0.97 to 1.27)
IM TC,
200 mg/4 weeks
0.12
(−1.00 to 1.25)
0.45
(−0.83 to 1.74)
0.24
(−1.10 to 1.59)
0.44
(−0.78 to 1.64)
0.36
(−0.89 to 1.63)
0.32
(−1.03 to 1.66)
0.41
(−0.92 to 1.74)
−0.08
(−1.32 to 1.18)
0.33
(−1.01 to 1.68)
0.60
(−0.46 to 1.67)
0.17
(−1.32 to 1.66)
0.04
(−1.20 to 1.28)
IM sustanon,
100 mg/2 weeks
−0.28
(−1.17 to 0.62)
0.05
(−1.05 to 1.14)
−0.16
(−1.32 to 1.01)
0.04
(−0.99 to 1.02)
−0.04
(−1.10 to 1.03)
−0.08
(−1.24 to 1.09)
0.01
(−1.13 to 1.16)
−0.48
(−1.52 to 0.57)
−0.07
(−1.24 to 1.11)
0.20
(−0.77 to 1.16)
−0.23
(−1.56 to 1.11)
−0.36
(−1.42 to 0.67)
−0.40
(−1.84 to 1.02)
IM durateston 250 mg/4weeks−0.37
(−1.49 to 0.74)
−0.05
(−1.33 to 1.24)
−0.26
(−1.61 to 1.09)
−0.06
(−1.27 to 1.12)
−0.14
(−1.37 to 1.13)
−0.18
(−1.51 to 1.16)
−0.08
(−1.40 to 1.23)
−0.57
(−1.81 to 0.66)
−0.17
(−1.52 to 1.17)
0.10
(−0.95 to 1.15)
−0.33
(−1.81 to 1.17)
−0.46
(−1.70 to 0.76)
−0.50
(−1.52 to 0.52)
−0.10
(−1.52 to 1.33)
  • *Random-effects model, with analysis based on mean change from baseline. A negative standardised mean difference indicates improvement in quality of life. Statistically significant changes are indicated by use of bold and colour (green indicates that the row treatment is significantly better than the column treatment), and white indicates no statistically significant difference between treatments.

  • IM, intramuscular injection; TC, testosterone cypionate; TE, testosterone enanthate; TU, testosterone undecanoate.